Biotech Notes

[tsongbird]

$BIEL Wearable, noninvasive, pulsed shortwave (radiofrequency) therapy for analgesia and opioid sparing following outpatient surgery: A proof-of-concept case series

Case report: Following moderately painful ambulatory umbilical (n = 3) and inguinal (n = 2) hernia repair as well as bilateral breast surgery (n = 2), patients had taped over their surgical incision(s) 1 or 2 noninvasive, wearable, disposable, pulsed shortwave therapy devices (RecoveryRx, BioElectronics Corporation, Frederick, Maryland) which functioned continuously for 30 days. Average resting pain scores measured on the 0-10 numeric rating scale were a median of 0 during the entire treatment period. Six patients avoided opioid use entirely, while the remaining individual required only 5 mg of oxycodone during the first postoperative day.

https://pubmed.ncbi.nlm.nih.gov/36463434/

[wendywilson123]

Creative Biogene provides commercial and research cell line based on its proprietary expression vector, high throughput cell screening technologies and serum, animal components free process without any adaptation issue in a significantly reduced timeline.

[djmurdock]

It's still an 11B market. And also the issues you are referring to are from longterm use. NSAIDS are obviously very effective, but even in short term use (days and weeks) can cause ulcers. This drug has solved that problem. Furthermore, if you looked into it more, you would see this drug makes naproxen much more powerful (and safer), so you have to take about 1/4 the normal dose of naproxen.

So I have to disagree with you. I don't think NSAIDS are going anywhere, anytime soon and at least there could be a much safer version of it soon.

[XenaLives]

NSAIDs cause a lot more negative issues than just ulcers and their use is in decline.

5 Key Dangers of NSAIDs + Other Common Side Effects
While pain medication has its uses, the dangers of NSAIDs are too great to ignore. These dangers of NSAIDs include risks for your heart, gastrointestinal tract and kidneys, among others.

1. Increased Risk of Heart Failure

Doctors have been concerned for some time that NSAIDs might play a role in heart failure since they cause consumers to retain sodium. Now, research just published in the British Medical Journal finds that NSAIDs increase the risk of heart failure by an alarming 19 percent. The risk directly rises with the amount of NSAIDs taken.

This study was based on the analysis of the medical history of millions of patients from four European countries (the Netherlands, Italy, Germany and the United Kingdom). The participants were all 18 years of age or older and had started NSAID treatment between 2000 and 2010. This large study specifically looked at the risk of hospital admission for heart failure and the use of 27 individual NSAIDs. The researchers found that current use of any NSAID was found to be associated with a 19 percent increase of risk of hospital admission for heart failure. (4)

Overall, the study found that seven traditional NSAIDs and two COX-2 inhibitors in particular led to an increased risk of heart failure.

Five NSAIDs in particular were linked to significant increased risk of heart failure admission:

Diclofenac,
Ibuprofen (brand name example: Motrin®)
Indomethacin
Ketorolac
Naproxen (brand name example: Aleve®)
Nimesulide
Piroxicam
The two COX-2 inhibitors are etoricoxib and rofecoxib, which are both currently not approved for use in the United States. When diclofenac, indomethacin, piroxicam, etoricoxib and rofecoxib were taken at “very high doses” (meaning two or more daily doses), the risk for heart failure doubled.

2. Gastrointestinal Damage, Ulcers and Internal Bleeding

NSAIDs all share the same most prevalent side effect — damage to the gastrointestinal tract, which doesn’t just mean your stomach. It also includes possible threats to your esophagus and small intestine. According to gastroenterologist Byron Cryer, MD, a spokesperson for the American Gastroenterological Association, more than half of all bleeding ulcers are caused by NSAIDs. (5)

Aspirin is the only NSAID that inhibits the blood clotting for a prolonged period of time (four to seven days), which is why many doctors recommend it for preventing blood clots that cause heart attacks and strokes. (6) While it may be successful at reducing blood clots, aspirin is an NSAID that’s especially known for causing gastrointestinal bleeding and ulcers. Anyone can develop a stomach ulcer while taking NSAIDs. Yes, that’s right — anyone. Being over 60 years old, smoking cigarettes, having multiple medical problems or having a family history of ulcers puts you at an even greater risk of experiencing stomach bleeding, one of the many dangers of NSAIDs.

Long-term or high-dose use of NSAIDs can also lead to ulcers developing in the gut. These are known as peptic ulcers. Peptic ulcers form because the action of NSAIDs block the COX-1 enzyme from protecting the stomach lining.

3. Higher Risk of Renal Failure

According to research published in the Journal of Clinical Pharmacology, NSAIDs have a negative effect on renal (kidney) health in essentially all patients using NSAIDs. The most common renal complication caused by NSAIDs is fluid retention, which is believed to occur on some level in anyone taking these man-made anti inflammatory pills. Clinically detectable edema occurs in less than 5 percent of patients. (7) Edema is a medical term for swelling caused by excess fluid being trapped in your body’s tissues. NSAIDs also encourage the body to hold on to sodium which can lead to varying degrees of reduction in kidney function. (8)

Complete avoidance of nonsteroidal anti-inflammatory drugs is recommended for most people with chronic kidney disease.

4. Serious Allergic Reactions

Some people are actually highly allergic to NSAIDs. For these individuals, the dangers of NSAIDs can include experiencing a scary shortness of breath. For an asthma sufferer, the risk of experiencing serious allergic reaction to NSAIDs is even higher. Other allergic reactions can include wheezing, rashes and throat swelling. If you have a serious allergic response to one NSAID then you’re likely to have a similar response to a different NSAID so you should avoid all NSAIDs. (9)

5. Dangers to Children and Teenagers

There are also specific dangers of NSAIDs for the younger population. The use of aspirin by children and teenagers with chickenpox or the flu has been associated with the development of Reye’s syndrome. This syndrome is rare yet serious. It can cause liver as well as brain damage, and sometimes even fatal liver disease or permanent brain damage. Aspirin and non-aspirin salicylates should never be used in children and teenagers with suspected or confirmed chickenpox or influenza. In general, children under the age of 16 should not take aspirin products. (10)

https://www.healthline.com/health/side-effects-from-nsaids

[djmurdock]

I highly recommend you check out Antibe Therapeutics $ATBPF for an investment and trading opportunity. To put it simply, they have created a safer version of NSAIDS (Naproxen, Asprin, etc). NSAIDS are notorious for causing ulcers. To say this is a large market is an understatement. Their final Phase2b results, which is the most crucial for bios, are out in a few weeks.

Not only is their drug much safer, it is also way stronger. A double victory. Their founder, John Wallace, is one of the top gastroenterologist in the world and is highly respected in his field.
https://en.wikipedia.org/wiki/John_L._Wallace

Reasons I like the stock/company:
For the target market it is extremely undervalued.
Last Phase2B results were incredible.
Very good team, their Chairman of board is the Vice Chairman of Mastercard!
Because it is Canadian it is very under the radar in the States (undervalued)
Uplisting to Nasdaq later this year.
Fully funded for the rest of trial and rest of year
Already have licensing deals
They hired Dr. Rami Batal, from Canopy fame," in the new role of Senior VP, Commercial Strategy. The creation of this position represents a further step in the Company’s partnering efforts for its lead drug, ATB-346, and for its overall drug platform."
Stock has been beaten down from all time highs due to this Corona nightmare, providing a great entry point.
Multiple analyst give this a price target of $1.30 and higher (with good results)

Negatives:
Low volume on the US side
That's about it LOL
Like any bio in testing phases if they fail it will tank
Based on 2 years of hardcore research, I give this about a 95% of having great results and a huge partnership and/or buyout later this year.
Disclosure: I am long $ATBPF

[XenaLives]

AGRX - Secondary after approval.

Has consolidated.

https://investorshub.advfn.com/Agile-Therapeutics-Inc-AGRX-28553/

[XenaLives]

BLPH - pulmonary treatment, non drug.

Recent R/S

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153969597

[XenaLives]

SEEL - Waiting for clarification of stock history here:

https://investorshub.advfn.com/Seelos-Therapeutics-Inc-SEEL-4393/

[XenaLives]

ACTC - Viral delivered gene therapy:

https://investorshub.advfn.com/Applied-Genetic-Technologies-Corporation-AGTC-7975/

[XenaLives]

We are entering the era of AI controlled healthcare.

This means that the arbitrary recommendations of over worked physicians will get double checked.

https://ih.advfn.com/stock-market/NASDAQ/mannkind-MNKD/stock-news/80471670/mannkind-and-one-drop-sign-collaboration-agreement

[XenaLives]

Epigenetic change due to environmental factors is a very real threat to humanity. It was great to see a company like this working on the problem:

HOMEABOUTSCIENCENEWS & EVENTSPARTNERINGCONTACTLINKEDINTWITTER
NEWS
3rd September 2018

STORM Therapeutics and the University of Cambridge receive Innovate UK funding to help the fight against cancer
STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, and The University of Cambridge announced today that they have been granted a Knowledge Transfer Partnership (KTP). The Grant, of up to £240,000, is to develop an analysis platform using the data warehouse software InterMine to help STORM advance its cancer research.

Read more

10th May 2018

STORM Therapeutics to present at Bio€quity Europe 2018
STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced that it will be giving a company presentation at Bio€quity Europe 2018, Ghent, Belgium, 14 - 16 May 2018.

Read more

27th March 2018

STORM Therapeutics wins Life Science Innovation Award
STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced that it has won the Life Science Innovation Award at the Business Weekly Awards ceremony.

Read more

29th January 2018

STORM Therapeutics Appoints Distinguished Professor and Nobel Prize Winner Professor Thomas Cech as Scientific Advisor
STORM Therapeutics today announced the appointment of Nobel Prize Winner Professor Thomas Cech as a Scientific Advisor. This appointment follows STORM Therapeutics’ successful Series A Financing Extension announced in January 2018.

Read more

8th January 2018

STORM Therapeutics Extends Series A Round to Include New Investor Taiho Ventures
Storm Therapuetics today announced that it has raised an additional £4 million of funding from Taiho Ventures, LLC the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd.

Read more

https://www.stormtherapeutics.com/news-events/news/

Thomas Cech
From Wikipedia, the free encyclopedia
Jump to navigationJump to search
Thomas Cech
Thomas Robert Cech.jpg
Thomas Cech
Born December 8, 1947 (age 71)
Chicago, USA
Alma mater Grinnell College (B.A., 1970)
University of California, Berkeley (Ph.D., 1975)
Massachusetts Institute of Technology (Postdoctoral)
Known for Ribozyme
Awards Newcomb Cleveland Prize (1986)
NAS Award in Molecular Biology (1987)
Nobel Prize in Chemistry (1989)
National Medal of Science (1995)
Othmer Gold Medal (2007)

Scientific career
Institutions University of Colorado, Howard Hughes Medical Institute
Thomas Robert Cech (born December 8, 1947) is an American chemist who shared the 1989 Nobel Prize in Chemistry with Sidney Altman, for their discovery of the catalytic properties of RNA. Cech discovered that RNA could itself cut strands of RNA, suggesting that life might have started as RNA.[1] He also studied telomeres, and his lab discovered an enzyme, TERT (telomerase reverse transcriptase), which is part of the process of restoring telomeres after they are shortened during cell division.[2] As president of Howard Hughes Medical Institute, he promoted science education, and he teaches an undergraduate chemistry course at the University of Colorado.

Research
Cech's main research area is that of the process of transcription in the nucleus of cells. He studies how the genetic code of DNA is transcribed into RNA. In the 1970s, Cech had been studying the splicing of RNA in the unicellular organism Tetrahymena thermophila when he discovered that an unprocessed RNA molecule could splice itself. In 1982, Cech became the first to show that RNA molecules are not restricted to being passive carriers of genetic information – they can have catalytic functions and can participate in cellular reactions. RNA-processing reactions and protein synthesis on ribosomes in particular are catalysed by RNA. RNA enzymes are known as ribozymes and have provided a new tool for gene technology. They also have the potential to provide new therapeutic agents – for example, they have the ability to destroy and cleave invading, viral RNAs.

Cech's second area of research is on telomeres, the structure that protects the ends of chromosomes. Telomeres are shortened with every duplication of DNA, and must be lengthened again. He studies telomerase, the enzyme that copies the telomeric sequences and lengthens them. The active site protein subunits of telomerase comprise a new class of reverse transcriptases, enzymes previously thought to be restricted to viruses and transposable elements. Telomerase is activated in 90% of human cancers. Therefore, a drug that would inhibit its activity could be useful in treating cancer.

https://en.wikipedia.org/wiki/Thomas_Cech

[XenaLives]

Healthcare is changing quickly and there are so many new and fascinating things going on that I just wanted to keep some notes in a public space to share and see if there were others that wanted to discuss this.

PLEASE - respectful posts on topic only.